SPARC Antibody AF941 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemSPARC Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberAF941
NCBI Gene AliasesON, OI17, BM-40, ONT
ApplicationsWestern Blot, Simple Western, ELISA, Immunohistochemistry, Intracellular Staining by Flow Cytometry, CyTOF-ready
Conjugate/TagUnconjugated
ReactivityHuman
IsotypeIgG
HostGoat
Quantity100 ug (also 25 ug)
TargetSPARC
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
NCBI Full Gene Namesecreted protein acidic and cysteine rich
ClonalityPolyclonal
ImmunogenMouse myeloma cell line NS0-derived recombinant human SPARC/Osteonectin, Ala18-Ile303, Accession # P09486
ConcentrationLYOPH
PurityAntigen Affinity-purified
Brand/TrademarkR&D Systems, a Bio-Techne Brand
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Unconjugated

Specificity: Detects human SPARC/Osteonectin in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse SPARC is observed, and less than 3% cross-reactivity with recombinant human SPARC L1 is observed

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Imaging of Indocyanine Green-Human Serum Albumin (ICG-HSA) Complex in Secreted Protein Acidic and Rich in Cysteine (SPARC)-Expressing GlioblastomaInternational journal of molecular sciencesJanuary 3, 2023Jang HJ, Song MG, Park CR, Youn H, Lee YS, Cheon GJ, Kang KW.BSA in PBS for 1 h at RT. After blocking, the samples were treated with anti-SPARC primary antibody (#AF941; R&D systems, Minnneapolis, MN, USA; diluted 1:10) in 0.5% BSA and incubated at 4 °C overnight. On the

(2) Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancersFrontiers in oncologyJanuary 1, 2023Kazakova E, Rakina M, Sudarskikh T, Iamshchikov P, Tarasova A, Tashireva L, Afanasiev S, Dobrodeev A, Zhuikova L, Cherdyntseva N, et al.rabbit anti-S100A4 (1:1000, PA5-82322, Thermo Fisher Scientific, USA), polyclonal goat anti-SPARC (1:80, AF941, R&D Systems, USA), polyclonal goat anti-SPP1 (1:80, AF1433, R&D Systems, USA). To visualize the antigen-antibody

(3) Mesenchymal stem cells induce tumor stroma formation and epithelial‑mesenchymal transition through SPARC expression in colorectal cancerOncology reportsJune 1, 2021Naito T, Yuge R, Kitadai Y, Takigawa H, Higashi Y, Kuwai T, Kuraoka K, Tanaka S, Chayama K.primary antibodies were used in the present study: Polyclonal goat anti-SPARC (dilution, 1:100; cat. no. AF941; R&D Systems, Inc.), monoclonal rat anti-PTX3 (dilution, 1:500; cat. no. ab90806; Abcam), monoclonal

(4) A non-immunological role for γ-interferon–inducible lysosomal thiol reductase (GILT) in osteoclastic bone resorptionScience AdvancesApril 23, 2021Benjamin W. Ewanchuk, Corey R. Arnold, Dale R. Balce, Priyatha Premnath, Tanis L. Orsetti, Amy L. Warren, Alexandra Olsen, Roman J. Krawetz, Robin M. YatesProtein Strep-Tactin HRP Conjugate (Bio-Rad). Equal SPARC loading was confirmed using goat α-human SPARC (AF941, R&D Systems) followed by a donkey α-goat IgG-HRP secondary antibody (sc-2020, Santa Cruz Biotechnology).

(5) Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agentNature CommunicationsDecember 1, 2020Xin Zeng et al.MO, USA). Primary antibodies, including those against human albumin (MAB1455, 1:500), human SPARC (AF941, 1:500) and mouse SPARC (MAB942, 1:500) were purchased from R&D Systems (MN, USA). Anti-mouse albumin

(6) Accumulation of stabilin-1 positive macrophages in the early stage of gastric cancer is associated with short cumulative survivalOncology lettersMarch 1, 2020Yin SP, Gao Y, Xie XS, Xu DD, Riabov V, Du WD.cat. no. 1607; R&D Systems Europe, Ltd.) and goat anti-human SPARC polyclonal antibody (1:60; cat. no. AF941; R&D Systems, Inc.). The primary antibodies were diluted in 0.01 M PBS (pH 7.4)/1% BSA buffer. Sections

(7) Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulationJournal of Controlled ReleaseMay 1, 2019Ji Eun Park et al.membranes were probed with the antibodies for hSPARC (1:200; R&D Systems, Minneapolis, MN, USA; Cat. No. AF941) and β-actin (Cell Signaling Technology, Danvers, MA, USA; Cat. No. 4970). After washing with TBST,

(8) Secreted protein acidic and rich in cysteine mediates active targeting of human serum albumin in U87MG xenograft mouse modelsTheranosticsJanuary 1, 2019Park CR, Jo JH, Song MG, Park JY, Kim YH, Youn H, Paek SH, Chung JK, Jeong JM, Lee YS, et al.with anti-CD31 primary antibody (AF3628, R&D system, diluted 1: 100) or anti-human SPARC antibody (AF941, R&D system, diluted 1: 200) in 1% BSA, TBS, and incubated at 4 °C overnight. On the following day,

(9) Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated NanocrystalsMolecular pharmaceuticsJanuary 29, 2018Gad SF, Park J, Park JE, Fetih GN, Tous SS, Lee W, Yeo Y.containing 0.05% Tween 20 (TBST) and probed with antibodies against hSPARC (dilution 1:200, R&D system; AF941), mSparc (dilution 1:1000, R&D system; AF942) and β-actin (dilution 1:1000, Cell Signaling). The membrane

(10) In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discoveryBritish journal of cancerNovember 21, 2017Zhang J, Hao N, Liu W, Lu M, Sun L, Chen N, Wu M, Zhao X, Xing B, Sun W, et al.NaCl, pH 7.5) containing 5% skim milk, membranes were incubated overnight at 4 °C with goat anti-SPARC (AF941; R&D Systems, Minneapolis, MN, USA) or goat anti-THBS2 (sc-7655; Santa Cruz Biotechnology, Santa Cruz,

(11) The relationship between stromal cell derived SPARC in human gastric cancer tissue and its clinicopathologic significanceOncotargetOctober 17, 2017Yi Gao, Shui-Ping Yin, Xu-Shi Xie, Dan-Dan Xu, Wei-Dong Duincubated with goat anti-human SPARC/osteonectin antigen affinity-purified polyclonal antibody (Catalogue # AF941, dilution 1:60, R&D systems, Minneapolis, MN, USA) at 3μg/ml. Approximately 100μl of the diluted primary

(12) Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse modelOncotargetMay 24, 2016Riabov V, Yin S, Song B, Avdic A, Schledzewski K, Ovsiy I, Gratchev A, Llopis Verdiell M, Sticht C, Schmuttermaier C, et al.at 80°C. Following primary anti-human antibodies were used: mouse CD68 (Zytomed), goat SPARC, clone AF941, goat CD163, sheep CD34 (all from R&D systems), rabbit anti-stabilin-1, clone RS1 (self-produced), mouse

(13) Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transitionOncology LettersMay 1, 2016DEHUAN SHI, KAN JIANG, YING FU, RUI FANG, X I LIU, JIE CHENSigma-Aldrich. The sections were incubated with goat polyclonal IgG anti-human SPARC (dilution, 1:500; #AF941; R&D Systems, Inc., Minneapolis, MN, USA), rabbit polyclonal IgG anti-human E-cadherin (dilution, 1:200;

(14) A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer BiomarkersPLOS ONESeptember 30, 2015Jesse V. Jokerst, Zuxiong Chen, Lingyun Xu, Rosalie Nolley, Edwin Chang, Breeana Mitchell, James D. Brooks, Sanjiv S. GambhirThe c.Ab (Invitrogen; p/n 33–5500 (On1-1)) was a mouse monoclonal, and the d. Ab (R&D Systems; p/n AF941) was a goal polyclonal. A recombinant protein standard (R&D Systems p/n 941-SP-050) validated the assay. •

(15) Automated Analysis and Classification of Histological Tissue Features by Multi-Dimensional Microscopic Molecular ProfilingPloS oneJanuary 1, 2015Riordan DP, Varma S, West RB, Brown PO.Primary antibodies were obtained from R&D Systems for Lyve-1 (AF2089), CTGF (AF660), SPARC/Osteonectin (AF941), Fzd7 (AFMAB1981), Dkk3 (AF1118), ACE (AF929), Beta-catenin/CTNNB1 (MAB13291), CD105/Endoglin (AF1097),

(16) Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinomaCancer researchFebruary 15, 2014Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA.

(17) Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasisBMC cancerOctober 10, 2012Chen J, Shi D, Liu X, Fang S, Zhang J, Zhao Y.membrane and blocked with 5% BSA. The membranes were first incubated with primary antibody against SPARC (AF941, R&D Systems), PCNA (bs-0754R, BIOSS), cyclin D1 (bs-0623R, BIOSS), P53 (bs-0033R, BIOSS), P21 (bs-0741R,

(18) The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer¹This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journal’s usual peer review processBiochemistry and Cell BiologyFebruary 1, 2012James B. Greenaway, Anne Koehler, Christopher A. McCulloch, James Petrik, Theodore J. Brown, Maurice J. Ringuettewere blocked in 3% (wt/vol) skim milk for 1 hr and incubated overnight with SPARC primary antibody (AF941, R&D Systems; goat polyclonal. Peroxidase-conjugated secondary antibody was applied for one hour at room

(19) SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancerPloS oneJanuary 1, 2012Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y.dewaxing, rehydration, and antigen retrieval, the sections were incubated with anti-human SPARC antibody (AF941, R&D Systems and bs-1133R, BIOSS) with working dilution 15 µg/ml for AF941 and 10 µg/ml for bs-1133R

(20) Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31Experimental cell researchApril 15, 2011Shen M, Siu S, Byrd S, Edelmann KH, Patel N, Ketchem RR, Mehlin C, Arnett HA, Hasegawa H.

Be the First to Write a Review!

Oncology reports

Oncology reports

PloS one

PloS one

PloS one

SPARC Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (21)

Reviews

SPARC Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map